Thromboembolism are highly prevalent and burdensome in patients with cancer. Risk for venous thromboembolism (VTE) varies widely across specific cancer patients. The ability to predict risk of cancer-associated VTE is critical because for an optimal thromboprophylaxis strategy. This means targeting high-risk patients with cancer and avoiding prophylaxis in cancer patients at low risk for VTE.

свернуть